• Explore /
  • Poster
  • / One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer.

One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer.

Abstract Poster

Authors

null

Yvonne Brandberg

Karolinska Institutet, Department of Oncology-Pathology (OnkPat), Karolinska University Hospital, Stockholm, Sweden

Yvonne Brandberg , Theodoros Foukakis , Anne Andersson , Judith Bjohle , Ana Bosch , Lena Carlsson , Zakaria Einbeigi , Hanna Fredholm , Erika Isaksson-Friman , Mats Hellstrom , Hemming Johansson , Tobias Lekberg , Henrik Lindman , Jonas C. S. Bergh , Thomas Hatschek

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT02568839

Citation

J Clin Oncol 38: 2020 (suppl; abstr 590)

DOI

10.1200/JCO.2020.38.15_suppl.590

Abstract #

590

Poster Bd #

82

Abstract Disclosures

Similar Posters

First Author: Yvonne Brandberg

First Author: Giampaolo Bianchini

First Author: Joseph B. Babigumira

First Author: WanChen Hsieh